Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Interleukin-2 × 90 days × Clear all

Phase

Status

Completed 10 Recruiting 8 Active not recruiting 7 Terminated 2 Not yet recruiting 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma of Lung 1

Interventions

pembrolizumab 5 Cyclophosphamide 4 fludarabine 3 Paclitaxel 3 fludarabine phosphate 2 decitabine and cedazuridine drug combination 2 aldesleukin 2 Magnetic Resonance Spectroscopy 2 Granulocyte Colony-Stimulating Factor 2 Filgrastim 2 Biopsy 2 zimberelimab 1 venetoclax 1 vedolizumab 1 tremelimumab 1 trastuzumab deruxtecan 1 tazemetostat 1 ribociclib 1 regorafenib 1 peginterferon alfa-2a 1 olaparib 1 lenvatinib 1 inavolisib 1 gallium 68 PSMA-11 1 enfortumab vedotin 1 durvalumab 1 capivasertib 1 bemarituzumab 1 atezolizumab 1 abemaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05566223 2026-02-23

CheckCell-2

Intima Bioscience, Inc.

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡